Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases

Company Overview - Avidity Biosciences, Inc. is a biopharmaceutical company focused on RNA therapeutics, specifically Antibody Oligonucleotide Conjugates (AOCs™) [4] - The company aims to improve lives by delivering innovative RNA therapies that combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies [4] - Avidity is leading clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD) [4] Industry Engagement - Avidity is actively participating in Rare Disease Day to raise awareness about rare diseases, particularly rare neuromuscular disorders [2][3] - The company supports various initiatives, including the EveryLife Foundation for Rare Diseases and the Jett Foundation's webinar on Duchenne muscular dystrophy [5] - Avidity collaborates with advocacy organizations, researchers, and healthcare providers to foster innovation and provide hope for those affected by rare diseases [3] Clinical Development - Avidity has demonstrated the first successful targeted delivery of RNA into muscle using its proprietary AOC platform [4] - The company is also advancing two precision cardiology development candidates aimed at addressing rare genetic cardiomyopathies [4] - Avidity is expanding its pipeline to include programs in cardiology and immunology through strategic partnerships [4]